Outlook Therapeutics Stock
Outlook Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robert Charles Jahr
- Employees
- 17
- Market cap
- $119 M
- IPO
- 14/06/2016
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing…
Outlook Therapeutics stock: price history
1D
-2.4%
1W
-18.5%
1M
-27.9%
6M
+57.9%
YTD
-69.1%
1Y
-63.6%
2Y
-90.6%
5Y
-98.8%
10Y
-99.9%
Next earnings date
Next earnings date
18/12/2026 (in 62 days)
Volatility around earnings
~20% weaker price swings than usual
Ask the agents about Outlook Therapeutics
Analyst assessment of Outlook Therapeutics
PRICE TARGET LOW
US$1.60
CONSENSUS
US$2.80
MEDIAN
US$2.80
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
8
BUY
6
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 11/09/2026
Outlook Therapeutics stock metrics
P/E
-0.26
P/B
-1.2
EV/EBITDA
-2.02
RETURN ON EQUITY
195.5%
NET MARGIN
-225,766.7%
DEBT/EQUITY
-1.77
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.8%
FLOAT SHARES
196,671,414
AVG. DAILY VOLUME (30D)
4,454,078
Insider transactions (SEC)
KENYON LAWRENCE A
Jahr Robert Charles
Sukhtian Ghiath M.
Sukhtian Faisal Ghiath
Haddadin Yezan Munther
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Outlook Therapeutics stock
What does Outlook Therapeutics do?
Outlook Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robert Charles Jahr, the company employs around 17 people.
The IPO was on 14/06/2016; the stock trades on NASDAQ under the ticker OTLK.
What do analysts say about Outlook Therapeutics stock?
14 analysts rate the stock, the consensus is Buy (as of 11/09/2026).
The average price target is US$2.80, ranging from US$1.60 to US$4.00, with a median of US$2.80.
This is an external assessment, not a statement by Market Jury.
When does Outlook Therapeutics report next?
The next earnings date is 18/12/2026.
Around past earnings, price swings were roughly -20% stronger than usual.
Does Outlook Therapeutics pay a dividend?
No, Outlook Therapeutics currently does not pay a dividend.
Which stocks are comparable to Outlook Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Outlook Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Outlook Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.